Bioinsider

10/21/2020

Have we figured out how a hyperinflammatory immune response affect biotherapeutics or is it still a black box? As of today, there is no investigative initiatives, thus a detailed risk assessment is imperative. For example, patients should be profiled for the potential to have anti-drug (i.e. antibody/biologic) antibodies and these patients should not be treated.

Read more to find out what experts agreed on at our last Friday Roundtable brainstorming session: https://bit.ly/3nCtoMC

To sign up for a follow-up discussion, click here: https://bit.ly/36S1Tc6

10/20/2020

Bioinsider Friday Roundtables are informal, moderated 1-hour discussions allowing participants from diverse backgrounds to network, brainstorm, exchange ideas, share experiences, and develop future collaborations around a focused topic.

In order to ensure effective discussions, Friday Roundtables will have a maximum of 15 attendees per discussion and are on a first-come, first-served basis so make sure to register TODAY! https://bit.ly/3dJOwfx

Upcoming Friday Roundtable Events:
👉October 23, 2020 – Impact of COVID-19 on Immunogenicity of Biologics
👉October 30, 2020 – Drug Shortage Challenges in the Time of COVID-19
👉November 6, 2020 – Addressing Clinical Trials during COVID-19 and the Dialogue with Regulatory Agency

10/19/2020

Does COVID-19-mediated hyper activation of the immune system result in dysregulation of immune responses?
Find out more by reading our recent brainstorming Friday Roundtable Insider Highlights: https://bit.ly/3nzRrMw

Due to high demand, Bioinsider will provide a follow-up Friday Roundtable to discuss and find potential solutions to these open questions. If you missed the first one, make sure to sign up for the follow-up Friday Roundtable this week! https://bit.ly/3jOR12y

10/16/2020

🔵 October 23, 2020 – Impact of COVID-19 on Immunogenicity of Biologics - moderated by Drs. Vibha Jawa and Narendra Chirmule
🔵 October 30, 2020 – Drug Shortage Challenges in the Time of COVID-19 - moderated by Drs. Mina Tadrous and Barry Power
🔵 November 6, 2020 – Addressing Clinical Trials during COVID-19 and the Dialogue with Regulatory Agencies - moderated by Drs. Mohamed Hassanein and Michael Partridge

10/14/2020

Join Drs. Vibha Jawa from Merck and Narendra Chirmule from SymphonyTech Biologics in an intimate brainstorming session at our Friday Roundtables to address the impact of COVID19 on immunogenicity of biologics.

This is a highly engaging and vibrant discussion with a selected group of experts to find potential solutions and insights to help move the industry forward. Only 15 seats for this discussion so don't wait too long to register: https://bit.ly/33MH3Jr

Join us and be part of solutions!

10/13/2020

With cases of COVID-19 rising every day, scientists developing biotherapeutics for other diseases are discussing the influence of COVID-19 on B-cell responses and how it might alter the immunogenicity risk of immune modulatory biologics.

✅ It is known that some patients induce robust neutralizing antibodies targeting the Spike protein, while other patients have poor antibody production.
✅ Contrasting observations further complicate the therapeutic relevance of neutralizing antibodies. These observations suggest a strong antibody response may not be therapeutically relevant for COVID-19.
✅ The proportion of antibody isotype (IgG1, IgA1, 2, …, IgM) is thought to be important.
✅ Currently, evidence points to that neutralizing antibodies do not induce an increased mutation rate for COVID-19.

Read more here: https://bit.ly/3dgagzf

What are your thoughts on this? Leave them in the comments below.

Join our experts from Merck and SymphonyTech Biologics to further discuss this issue: https://bit.ly/33MH3Jr

Insider Highlights from Bioinsider’s Friday Roundtable, “How COVID-19 has Changed the Immunogenicity Risk of Immune Modulatory Biologics”

10/08/2020

The current pandemic is causing severe supply shortages of several notable drugs, according to the FDA and ASHP.

Check out this article for more details: https://bit.ly/34mm7YN

If you are interested in discussing drug shortages during the pandemic, join Bioinsider’s Friday Roundtable event on October, 30th for a valuable brainstorming session with experts and peers. Register now before it's sold out: https://bit.ly/3iBkQlG

Drugs needed to treat COVID-19, as well as unrelated drugs, are now in short supply.

10/07/2020

Recent coverage on one of our speakers at the Therapeutic Pipeline for COVID19 on BioSpace!

“As first generation therapeutics for COVID-19 struggle, we must learn why they struggle and how to address their limitations,” said Dr. Daniel Chen, M.D. Ph.D., CMO at IGM Biosciences, Inc., discussing the therapeutic pipeline for COVID-19. Read more on what Dr. Chen has to say: https://bit.ly/36w3FzB

If you missed this meeting, you can check the on-demand recordings for latest updates on COVID-19 therapeutic research here: https://bit.ly/33uYfCX

First-generation therapeutics have been largely ineffective against the SARS-CoV-2 virus, resulting in significant challenges and opportunities for the second-generation therapeutics that are being designed now.

10/06/2020

More research is rapidly needed to understand immunogenicity of COVID19 in its natural pathogenesis in order to identify potential responders and non-responders to biotherapeutic therapies.

Read the insights concluded in a recent FridayRoundtable hosted by Bioinsider discussing How COVID-19 has Changed the Immunogenicity Risk of Immune Modulatory Biologics: https://bit.ly/30B9pEn

Critical questions posed in the recent Bioinsider's Friday Roundtable Discussion:
☑ Does COVID-19-mediated hyper activation of the immune system result in dysregulation of immune responses?
☑ How does a hyperinflammatory immune response affect biotherapeutics?
☑ What is the influence of COVID-19 on B-cell responses?
☑ What about use of immune checkpoint inhibitor antibodies to treat COVID-19?

Due to high demand, Bioinsider will provide a follow-up Friday Roundtable to discuss and find potential solutions to open questions listed in this Insider Highlights on Oct. 23.

If you missed the first one, make sure to sign up for the follow-up Friday Roundtable on this topic here: https://bit.ly/2GB0b3Z

Insider Highlights from Bioinsider’s Friday Roundtable, “How COVID-19 has Changed the Immunogenicity Risk of Immune Modulatory Biologics”

09/23/2020

Did you miss the Therapeutic Pipeline for COVID-19 Virtual Meeting last week? No worries, you can still download and watch all the sessions here: https://bit.ly/35YAeGd

09/16/2020

Are you ready for tomorrow?

Our Therapeutic Pipeline for COVID-19 Virtual Meeting is coming up in less than 24 hours!

What to expect at the meeting?

The meeting provides the latest updates on COVID-19 therapeutic research through a panel of experts. Grow your network through our Speed Networking sessions and build professional relationships by brainstorming in intimate face-to-face breakout discussions with experts and peers.

Do not miss the chance to engage in fruitful discussions with Drs. Sina Bavari, Karl Voelkerding, Marco Schito, Joshua Schiffman, MD, Ruixin (Rachel) Hao, Daniel Chen, M.D. Ph.D., James Crowe, Aaron Sato, Davide Corti, Stefanie Kall, Ph.D., Rolf Hilgenfeld, Aashish Manglik, George Diaz, Laura Walker.

Only few slots left! Reserve your 'seat' now: https://bit.ly/2GXXtpa

09/14/2020

“The era for antibody interventions to prevent or treat infectious diseases is finally upon us” says Dr. James Crowe ,MD, Director of Vanderbilt Vaccine Center. Dr. Crowe is focused on characterizing the antibody and Bcell response of humans to sarscov2 infection to isolate potent neutralizing antibodies.

Check out the full interview here: https://bit.ly/3mkcwcW

09/11/2020

What to expect at the Therapeutic Pipeline for COVID-19 Meeting?
• One-day live meeting
• Get latest updates on COVID-19 therapeutic research
• Expand your network through Speed Networking sessions
• Build connections and exchange ideas through intimate face-to-face breakout discussions

Do not miss the chance to engage in fruitful discussions! Space is limited so grab your pass while you can: https://bit.ly/2GFpCBd

09/03/2020

Drug repurposing is an important strategy in facing COVID-19. Join Dr. Marco Schito, PhD, Executive Director of CURE Drug Repurposing Collaboratory from Critical Path Institute (C-Path) in a breakout discussion to brainstorm and share experiences about COVID-19 drug repurposing efforts and challenges.

In order to ensure effective discussion, breakout discussions will have a maximum of 10-15 attendees per room and are on a first-come, first-served basis.

Link: https://bit.ly/3hXJtcw

09/01/2020

Drug repurposing is an important strategy in facing COVID-19. Join Dr. Marco Schito, PhD, Executive Director of CURE Drug Repurposing Collaboratory from Critical Path Institute in a breakout discussion to brainstorm and share experiences about COVID-19 drug repurposing efforts and challenges.

In order to ensure effective discussion, breakout discussions will have a maximum of 10-15 attendees per room and are on a first-come, first-served basis.

Link: https://bit.ly/3hXJtcw

08/27/2020

There are 21 days left until the Therapeutic Pipeline for COVID-19 Virtual Meeting so we are giving out FREE PASSES to the first 21 members who either leave a question for our speakers or comment on COVID-19 therapeutics in the comments below. Be curious, participate and get your free pass now!

Check out the full program here to get your thoughts going and leave your question or comment down below! https://bit.ly/32tGjXx

We are giving out free passes across all of our social media channels and so there are just a few passes left!

08/26/2020

"Pandemics make for strange bedfellows and behavior in the pharmaceutical industry." https://lnkd.in/echFyat

Check out other efforts and collaborations at the upcoming Therapeutic Pipeline for COVID-19 Virtual Meeting on Sept. 17: https://bit.ly/31txopJ

Pandemics make for strange bedfellows.